Patients with type 2 diabetes who were fasting throughout Ramadan were given either liraglutide, a GLP-1 receptor agonist, or sulphonylurea as a supplementary medicine to metformin in the Treat 4 Ramadan investigation [43]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.